CytoMed Therapeutics Has Obtained Board Approval To Launch, Pilot Program To Isolate And Cryo-Store Peripheral Blood Mononuclear Cells For And As A Reward To Loyal Shareholders Of CytoMed On Complimentary Basis, The Program Will Commence On June 1, 2024
CytoMed Therapeutics Has Obtained Board Approval To Launch, Pilot Program To Isolate And Cryo-Store Peripheral Blood Mononuclear Cells For And As A Reward To Loyal Shareholders Of CytoMed On Complimentary Basis, The Program Will Commence On June 1, 2024
CytoMed Therapeutics已獲得董事會批准啓動試點計劃，該計劃將於2024年6月1日啓動，該計劃將分離和冷凍儲存外周血單個核細胞，作爲對CytoMed忠實股東的免費獎勵
CytoMed Therapeutics Has Obtained Board Approval To Launch, Pilot Program To Isolate And Cryo-Store Peripheral Blood Mononuclear Cells For And As A Reward To Loyal Shareholders Of CytoMed On Complimentary Basis, The Program Will Commence On June 1, 2024
CytoMed Therapeutics已獲得董事會批准啓動試點計劃，該計劃將於2024年6月1日啓動，該計劃將分離和冷凍儲存外周血單個核細胞，作爲對CytoMed忠實股東的免費獎勵
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。